Risk factors for time to advanced neoplasia during follow-up
| Advanced neoplasia during surveillance | Univariate HR (95% CI) | P value | Multivariable HR* (95% CI) | P value | ||
| No | Yes | |||||
| Gender, n (%) | ||||||
| Male | 83 (64%) | 47 (36%) | 1 | 1 | ||
| Female | 90 (64%) | 51 (36%) | 0.95 (0.64 to 1.41) | 0.81 | 0.99 (0.66 to 1.50) | 0.97 |
| Smoking status | ||||||
| Never smoker | 56 (70%) | 24 (30%) | 1 | 1 | ||
| Former smoker | 46 (65%) | 25 (35%) | 1.22 (0.71 to 2.08) | 0.48 | 1.20 (0.68 to 2.13) | 0.52 |
| Current smoker | 58 (69%) | 26 (31%) | 1.10 (0.62 to 1.95) | 0.75 | 1.09 (0.61 to 1.95) | 0.76 |
| WHO criterion at study inclusion† | ||||||
| WHO I | 56 (57%) | 43 (43%) | 1 | 1 | ||
| WHO III | 77 (78%) | 22 (22%) | 0.38 (0.22 to 0.63) | <0.001 | 0.38 (0.22 to 0.64) | <0.001 |
| WHO I and III | 40 (55%) | 33 (45%) | 0.91 (0.58 to 1.43) | 0.68 | 0.89 (0.56 to 1.40) | 0.6 |
| Age at SPS diagnosis | 0.98 (0.96 to 1.01) | 0.15 | 0.99 (0.96 to 1.01) | 0.16 | ||
| ≥1 advanced adenomas‡ | ||||||
| No | 93 (66%) | 47 (34%) | 1 | 1 | ||
| Yes | 80 (61%) | 51 (39%) | 1.21 (0.82 to 1.80) | 0.34 | 1.24 (0.82 to 1.87) | 0.31 |
| ≥1 advanced SP‡ | ||||||
| No | 45 (69%) | 20 (31%) | 1 | 1 | ||
| Yes | 128 (62%) | 78 (38%) | 1.46 (0.89 to 2.39) | 0.13 | 1.46 (0.89 to 2.40) | 0.13 |
| ≥1 SP proximal to splenic flexure† | ||||||
| No | 27 (59%) | 19 (41%) | 1 | 1 | ||
| Yes | 146 (65%) | 79 (35%) | 0.84 (0.51 to 1.38) | 0.49 | 0.86 (0.51 to 1.43) | 0.95 |
| ≥1 SP with dysplasia‡ | ||||||
| No | 131 (62%) | 79 (38%) | 1 | 1 | ||
| Yes | 42 (69%) | 19 (31%) | 0.82 (0.50 to 1.36) | 0.44 | 0.84 (0.51 to 1.39) | 0.5 |
| ≥1 SP≥10 mm and ≥1 advanced adenoma‡ | ||||||
| No | 167 (65%) | 91 (35%) | 1 | 1 | ||
| Yes | 6 (46%) | 7 (54%) | 1.270 (0.59 to 2.74) | 0.54 | 1.21 (0.56 to 2.64) | 0.63 |
| CRC‡ | ||||||
| No | 131 (64%) | 73 (36%) | 1 | 1 | ||
| Yes | 42 (63%) | 25 (37%) | 1.14 (0.74 to 1.80) | 0.56 | 0.80 to 2.07 | 0.31 |
↵*Adjusted for potential confounders: age, gender and smoking status.
↵†WHO criterion I: ≥5 SP proximal to sigmoid colon with at least two being ≥10 mm in diameter; WHO criterion III: ≥20 SP of any size, spread throughout the colon.5
↵‡Diagnosed prior to or during clearing phase.
CRC, colorectal cancer; SP, serrated polyp; SPS, serrated polyposis syndrome.